IDXX · IDEXX LABORATORIES INC

Back to holdings

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.

Close · 3M

-14.93%

Held by 0 AI ETFs

None of the tracked AI ETFs currently hold this name.

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals2

Win rate0% (0/2)

Avg buy return-5.16%

AIEQno longer held2 signals

AIEQ · Exit · 1d

IDEXX LABORATORIES INC presented with a PER of 39.69 and a PBR of 33.65, indicative of elevated valuation multiples, even as it maintained a 70.87% ROE and 13.08% revenue growth. AIEQ, leveraging IBM Watson NLP for its 'fundamentals + sentiment hybrid' approach, likely interpreted a shift in the market's perception or updated fundamental signals despite these profitability metrics. The stock's 90-day return showing a -13.7% decline, placing it at 70% of its 52-week high, provided a price context for this evolving sentiment. On 2026-07-01, the daily ranking output from Watson, filtered through EquBot's risk overlay, prompted AIEQ’s high-turnover strategy to fully divest its 0.0900% position in IDXX at a price near $537.58, reflecting the new assessment.

weight 0.090% → 0 (exited)·stock down 5.2% in the 30 days before

Jul 1·entry $537.58·now $540.68

+0.58%

since Jul 1

AIEQ · New entry · 1d

The AI ETF likely initiated a position in IDXX due to its exceptionally high ROE of 69.78% and solid 10.42% revenue growth, indicating the system prioritizes strong profitability and operational efficiency despite the elevated P/E and P/B ratios. For retail investors, this highlights that advanced algorithms may favor companies with outstanding financial quality and growth potential, even at a premium valuation, so always conduct thorough due diligence on richly valued stocks.

weight 0 → 0.070% (new)·stock up 0.5% in the 30 days before

May 3·entry $563.12·now $540.68Fresh

-3.98%

since May 3

QRFTno longer held2 signals

QRFT · Exit · 1d

QRFT’s AI-driven strategy, which combines traditional factors like momentum and value with proprietary alternative data overlays, prompted IDEXX’s removal from its approximately 300 US large-cap portfolio. The fund's weekly rebalancing cadence allowed for this prompt divestment of the health care stock. IDEXX’s 90-day return of -20.6% and a PER of 40.15 likely triggered signals indicating it no longer aligned with the AI’s broad large-cap core selection criteria. This action reflects the continuous optimization by Qraft AI to maintain the portfolio’s desired factor exposures and overall health.

weight 0.100% → 0 (exited)·stock down 2.9% in the 30 days before

Jun 2·entry $550.82·now $540.68

-1.84%

since Jun 2

QRFT · New entry · 1d

weight 0 → 0.110% (new)·stock down 8.5% in the 30 days before

Mar 20·entry $577.26·now $540.68Fresh

-6.34%

since Mar 20

PQUSno longer held1 signal

PQUS · Exit · 1d

IDEXX Laboratories was removed from the PQUS portfolio on May 29th, at a price of $568.03, following a significant 17.2% decline in its stock value over the preceding 90 days, placing it at 74% of its 52-week high. The AI ranking system employed by Pictet Asset Management's US large-cap fund likely re-evaluated IDEXX's position during its periodic rebalance. Despite its 13.08% revenue growth and a 70.87% return on equity, the combination of high valuation metrics—a PER of 40.68 and a PBR of 33.65—coupled with the sustained recent price depreciation, contributed to the AI's decision. This systematic divestment on a specific rebalance date reflects the fund's measured turnover approach for its ~165 stock portfolio, where IDEXX no longer met the quantitative inclusion thresholds.

weight 0.080% → 0 (exited)·stock up 1.8% in the 30 days before

May 29·entry $563.53·now $540.68

-4.05%

since May 29

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of May 4

AI ETF AIEQ recently made a new entry into IDEXX, suggesting a positive outlook or growth expectation from an algorithmic perspective. This contrasts with the framework's 'Fail' verdict, which identifies significant concerns regarding financial data availability and the current valuation's lack of margin of safety.

Circle of CompetenceThe animal health diagnostics market generally exhibits stable demand and recurring revenue from consumables, allowing for reasonably predictable long-term cash flow projections within the circle of competence.
Economic MoatIDEXX likely possesses an economic moat through high switching costs for veterinary practices integrated into its diagnostic platforms and recurring consumable sales.
ManagementThere is insufficient data provided to assess management's candor, capital allocation discipline, or skin in the game as required by the framework.
Financial HealthThe provided financials are insufficient to evaluate the 10-year average ROE, operating margin stability, debt manageability, or owner earnings against the framework's strict criteria.
Margin of SafetyThe current valuation multiples, including a PER of 42.54 and EV/EBITDA of 43.83, suggest a high premium, leaving no apparent margin of safety.

IDEXX passes the initial screens for circle of competence and economic moat, suggesting a fundamentally strong business. However, the lack of comprehensive historical financial data prevents a full assessment of financial health, and the current high valuation multiples indicate a clear absence of a margin of safety, leading to an overall 'Fail' verdict.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.